Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC); European Society of Mycobacteriology (ESM); European Respiratory Society (ERS); Tuberculosis Network European Trials group (TBnet)

doi:10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), Tuberculosis Network European Trials group (TBnet)

Research output: Contribution to Journal › Comment / Letter to the editor › Academic

Original language	English
Article number	2200388
Pages (from-to)	1-3
Number of pages	3
Journal	European Respiratory Journal
Volume	59
Issue number	5
Early online date	19 May 2022
DOIs	https://doi.org/10.1183/13993003.00388-2022
Publication status	Published - May 2022

Bibliographical note

Funding Information:
Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

Funding

Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

Funders	Funder number
Deutsches Zentrum für Infektionsforschung
German Center of Infection Research

Keywords

Antibiotics, Antitubercular/therapeutic use
Antitubercular Agents/therapeutic use
Drug Therapy, Combination
Europe
Humans
Rifampin/analogs & derivatives
Tuberculosis/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1183/13993003.00388-2022

Persistent URL (handle)

Persistent link

Cite this

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), & Tuberculosis Network European Trials group (TBnet) (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 59(5), 1-3. Article 2200388. https://doi.org/10.1183/13993003.00388-2022

@article{d90bdc8ae2434590968b48797208699a,

title = "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component",

keywords = "Antibiotics, Antitubercular/therapeutic use, Antitubercular Agents/therapeutic use, Drug Therapy, Combination, Europe, Humans, Rifampin/analogs & derivatives, Tuberculosis/drug therapy",

author = "Lorenzo Guglielmetti and Gunar G{\"u}nther and Claude Leu and Daniela Cirillo and Raquel Duarte and Garcia-Basteiro, {Alberto L.} and Delia Goletti and Mateja Jankovic and Liga Kuksa and Maurer, {Florian P.} and Fr{\'e}d{\'e}ric M{\'e}cha{\"i} and Simon Tiberi and {Van Leth}, Frank and Nicolas Veziris and Christoph Lange and Hasan Hafizi and Naira Khachatryan and Harut Aroyan and Eduard Kabasakalyan and Michael Knappik and Alena Skrahina and Dzmitry Klimuk and Alena Nikolenka and Inge Muylle and Vladimir Milanov and Desislava Velkovska and Neli Tarinska and Elizabeta Bachiyska and Despo Pieridou and Tonia Adamide and Nicos Nicolaou and Martina Vasakova and Mariia Sukholytka and Emilia Kopeck{\`a} and Beata Polakova and Anderson, {Aase Bengard} and Folkvardsen, {Dorte Bek} and Erik Svensson and Manfred Danilovits and Tiina Kummik and Tuula Vasankari and Mathilde Fr{\'e}chet-Jachym and Audrey Nahmiash and Tamar Togonidze and Zaza Avaliani and Inga Kinkladze and Rusudan Aspindzelashvili and Teona Bichashvili and Gulnazi Losaberidze and Tsitsino Merabishvili and Barbara Kalsdorf and {Katerina Manika}, Manika and {Karyofyllis Tsiakitzis}, Tsiakitzis and Agnes Bakos and {\AE}gisd{\'o}ttir, {Tinna R{\'a}n} and Michelsen, {Gudr{\'u}n Svanhv{\'i}t} and Krist{\'i}n Karlsd{\'o}ttir and McLaughlin, {Anne Marie} and Margaret Fitzgibbon and Daniel Chemtob and Codecasa, {Luigi R.} and Maurizio Ferrarese and Stefania Torri and Majlinda Gjocaj and Edita Davidaviciene and Gil Wirtz and Monique Perrin and Asciak, {Analita Pace} and Dumitri Chesov and {De Lange}, Wiel and Onno Akkerman and Biljana Illievska-Poposka and Ulrich MacK and Mogens Jesenius and Lajla Kvalvik and Mengshoel, {Anne Torunn} and Katarzyna Kruzak and Nadine Ribeiro and Elmira Ibraim and Anna Kaluzhenina and Olga Barkanova and Dragica Pesut and Ivan Solovic and Petra Svetina and {De Souza-Galv{\~a}o}, {Maria Luiza} and Millet, {Joan Pau} and Xavi Casas and Montserrat Vives and Judith Bruchfeld and Paulina Dalemo and Jerker Jonsson and Katrin Aeschbacher and Peter Keller and Seref Ozkara and Christabelle Chen and Yana Terleeva and Andrii Dudnyk and {Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)} and {European Society of Mycobacteriology (ESM)} and {European Respiratory Society (ERS)} and {Tuberculosis Network European Trials group (TBnet)}",

note = "Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

month = may,

doi = "10.1183/13993003.00388-2022",

language = "English",

volume = "59",

pages = "1--3",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) & Tuberculosis Network European Trials group (TBnet) 2022, 'Rifapentine access in Europe: growing concerns over key tuberculosis treatment component', European Respiratory Journal, vol. 59, no. 5, 2200388, pp. 1-3. https://doi.org/10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. / Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC); European Society of Mycobacteriology (ESM); European Respiratory Society (ERS) et al.
In: European Respiratory Journal, Vol. 59, No. 5, 2200388, 05.2022, p. 1-3.

Research output: Contribution to Journal › Comment / Letter to the editor › Academic

TY - JOUR

T1 - Rifapentine access in Europe

T2 - growing concerns over key tuberculosis treatment component

AU - Guglielmetti, Lorenzo

AU - Günther, Gunar

AU - Leu, Claude

AU - Cirillo, Daniela

AU - Duarte, Raquel

AU - Garcia-Basteiro, Alberto L.

AU - Goletti, Delia

AU - Jankovic, Mateja

AU - Kuksa, Liga

AU - Maurer, Florian P.

AU - Méchaï, Frédéric

AU - Tiberi, Simon

AU - Van Leth, Frank

AU - Veziris, Nicolas

AU - Lange, Christoph

AU - Hafizi, Hasan

AU - Khachatryan, Naira

AU - Aroyan, Harut

AU - Kabasakalyan, Eduard

AU - Knappik, Michael

AU - Skrahina, Alena

AU - Klimuk, Dzmitry

AU - Nikolenka, Alena

AU - Muylle, Inge

AU - Milanov, Vladimir

AU - Velkovska, Desislava

AU - Tarinska, Neli

AU - Bachiyska, Elizabeta

AU - Pieridou, Despo

AU - Adamide, Tonia

AU - Nicolaou, Nicos

AU - Vasakova, Martina

AU - Sukholytka, Mariia

AU - Kopeckà, Emilia

AU - Polakova, Beata

AU - Anderson, Aase Bengard

AU - Folkvardsen, Dorte Bek

AU - Svensson, Erik

AU - Danilovits, Manfred

AU - Kummik, Tiina

AU - Vasankari, Tuula

AU - Fréchet-Jachym, Mathilde

AU - Nahmiash, Audrey

AU - Togonidze, Tamar

AU - Avaliani, Zaza

AU - Kinkladze, Inga

AU - Aspindzelashvili, Rusudan

AU - Bichashvili, Teona

AU - Losaberidze, Gulnazi

AU - Merabishvili, Tsitsino

AU - Kalsdorf, Barbara

AU - Katerina Manika, Manika

AU - Karyofyllis Tsiakitzis, Tsiakitzis

AU - Bakos, Agnes

AU - Ægisdóttir, Tinna Rán

AU - Michelsen, Gudrún Svanhvít

AU - Karlsdóttir, Kristín

AU - McLaughlin, Anne Marie

AU - Fitzgibbon, Margaret

AU - Chemtob, Daniel

AU - Codecasa, Luigi R.

AU - Ferrarese, Maurizio

AU - Torri, Stefania

AU - Gjocaj, Majlinda

AU - Davidaviciene, Edita

AU - Wirtz, Gil

AU - Perrin, Monique

AU - Asciak, Analita Pace

AU - Chesov, Dumitri

AU - De Lange, Wiel

AU - Akkerman, Onno

AU - Illievska-Poposka, Biljana

AU - MacK, Ulrich

AU - Jesenius, Mogens

AU - Kvalvik, Lajla

AU - Mengshoel, Anne Torunn

AU - Kruzak, Katarzyna

AU - Ribeiro, Nadine

AU - Ibraim, Elmira

AU - Kaluzhenina, Anna

AU - Barkanova, Olga

AU - Pesut, Dragica

AU - Solovic, Ivan

AU - Svetina, Petra

AU - De Souza-Galvão, Maria Luiza

AU - Millet, Joan Pau

AU - Casas, Xavi

AU - Vives, Montserrat

AU - Bruchfeld, Judith

AU - Dalemo, Paulina

AU - Jonsson, Jerker

AU - Aeschbacher, Katrin

AU - Keller, Peter

AU - Ozkara, Seref

AU - Chen, Christabelle

AU - Terleeva, Yana

AU - Dudnyk, Andrii

AU - Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)

AU - European Society of Mycobacteriology (ESM)

AU - European Respiratory Society (ERS)

AU - Tuberculosis Network European Trials group (TBnet)

N1 - Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022/5

Y1 - 2022/5

KW - Antibiotics, Antitubercular/therapeutic use

KW - Antitubercular Agents/therapeutic use

KW - Drug Therapy, Combination

KW - Europe

KW - Humans

KW - Rifampin/analogs & derivatives

KW - Tuberculosis/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85130397640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130397640&partnerID=8YFLogxK

U2 - 10.1183/13993003.00388-2022

DO - 10.1183/13993003.00388-2022

M3 - Comment / Letter to the editor

C2 - 35589114

SN - 0903-1936

VL - 59

SP - 1

EP - 3

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

M1 - 2200388

ER -

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), Tuberculosis Network European Trials group (TBnet). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal. 2022 May;59(5):1-3. 2200388. Epub 2022 May 19. doi: 10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Cite this